244 related articles for article (PubMed ID: 28974548)
1. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
Yu Z; He S; Wang D; Patel HK; Miller CP; Brown JL; Hattersley G; Saeh JC
Clin Cancer Res; 2017 Dec; 23(24):7608-7620. PubMed ID: 28974548
[No Abstract] [Full Text] [Related]
2. Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.
Wei L; Gao H; Yu J; Zhang H; Nguyen TTL; Gu Y; Passow MR; Carter JM; Qin B; Boughey JC; Goetz MP; Weinshilboum RM; Ingle JN; Wang L
Cancer Res; 2023 Feb; 83(3):456-470. PubMed ID: 36469363
[TBL] [Abstract][Full Text] [Related]
3. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
[No Abstract] [Full Text] [Related]
4. A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
LoRusso P; Hamilton E; Ma C; Vidula N; Bagley RG; Troy S; Annett M; Yu Z; Conlan MG; Weise A
Clin Breast Cancer; 2022 Jan; 22(1):67-77. PubMed ID: 34565686
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
6. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
[TBL] [Abstract][Full Text] [Related]
7. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD
Nat Med; 2021 Feb; 27(2):310-320. PubMed ID: 33462444
[TBL] [Abstract][Full Text] [Related]
8. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
9. Targeting androgen receptor in estrogen receptor-negative breast cancer.
Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Liu XS; Brown M
Cancer Cell; 2011 Jul; 20(1):119-31. PubMed ID: 21741601
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
Peters AA; Buchanan G; Ricciardelli C; Bianco-Miotto T; Centenera MM; Harris JM; Jindal S; Segara D; Jia L; Moore NL; Henshall SM; Birrell SN; Coetzee GA; Sutherland RL; Butler LM; Tilley WD
Cancer Res; 2009 Aug; 69(15):6131-40. PubMed ID: 19638585
[TBL] [Abstract][Full Text] [Related]
11. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
D'Amato NC; Gordon MA; Babbs B; Spoelstra NS; Carson Butterfield KT; Torkko KC; Phan VT; Barton VN; Rogers TJ; Sartorius CA; Elias A; Gertz J; Jacobsen BM; Richer JK
Mol Cancer Res; 2016 Nov; 14(11):1054-1067. PubMed ID: 27565181
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
13. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells.
Lin HY; Sun M; Lin C; Tang HY; London D; Shih A; Davis FB; Davis PJ
J Steroid Biochem Mol Biol; 2009 Feb; 113(3-5):182-8. PubMed ID: 19159686
[TBL] [Abstract][Full Text] [Related]
14. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
15. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G
J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516
[TBL] [Abstract][Full Text] [Related]
16. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
17. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
[TBL] [Abstract][Full Text] [Related]
18. Revisiting Androgen Receptor Signaling in Breast Cancer.
Dai C; Ellisen LW
Oncologist; 2023 May; 28(5):383-391. PubMed ID: 36972361
[TBL] [Abstract][Full Text] [Related]
19. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.
Garay JP; Karakas B; Abukhdeir AM; Cosgrove DP; Gustin JP; Higgins MJ; Konishi H; Konishi Y; Lauring J; Mohseni M; Wang GM; Jelovac D; Weeraratna A; Sherman Baust CA; Morin PJ; Toubaji A; Meeker A; De Marzo AM; Lewis G; Subhawong A; Argani P; Park BH
Breast Cancer Res; 2012 Feb; 14(1):R27. PubMed ID: 22321971
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines.
Rizza P; Barone I; Zito D; Giordano F; Lanzino M; De Amicis F; Mauro L; Sisci D; Catalano S; Dahlman Wright K; Gustafsson JA; Andò S
Breast Cancer Res; 2014 Feb; 16(1):R21. PubMed ID: 24552459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
